(RTTNews) - Revolution Medicines (RVMD) on Thursday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for RASONQUE (daraxonrasib) to treat adults with metastatic pancreatic adenocarcinoma who have re
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.